Key facts
- Fluid Biomed’s last known valuation is $3.9M (Dec 2019).
- It has raised $32.5M; the latest was Later Stage VC in Aug 2025.
- Notable investors include Creative Destruction Lab, MedTech Innovator, Amino Capital, IAG Capital Partners, ShangBay Capital — 24 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for Fluid Biomed
- ·The full record, as it builds
Funding rounds
No funding rounds for Fluid Biomed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Fluid Biomed
Developer of polymer-based medical devices designed to commercialize the next generation of stents to heal blood vessels. The company's device is a revolutionary implantable bio-absorbable polymer-based flow-diverting stent designed to gently divert blood flow to heal a weakened brain aneurysm, enabling physicians to efficiently and quickly treat patients and prevent stroke.
- Sector
- Healthcare
- HQ
- Calgary, Canada
- Founded
- 2012
- Employees
- 13
- Website
- fluidbiomed.com/
- Ownership
- Privately Held (backing)
Fluid Biomed doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Fluid Biomed shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Fluid Biomed in its N-PORT filings yet. We sweep new filings monthly.